Thu, Jun 26, 9:11 PM (18 days ago)
### Abstract/Summary of Aethlon Medical, Inc. (AEMD) 10-K Filing **Financial Performance:** - **Revenue:** No revenue was generated during the fiscal years ended March 31, 2025 and 2024. - **Net Income:** The company reported a net loss of $13,388,089 for the fiscal year ended March 31, 2025, compared to a net loss of $12,208,174 for the fiscal year ended March 31, 2024. - **Operating Expenses:** Total operating expenses were $9,341,364 for the fiscal year ended March 31, 2025, compared to $12,636,568 for the fiscal year ended March 31, 2024. **Strategic Overview:** - **Oncology:** The company is conducting clinical trials in Australia for the Hemopurifier® (HP) in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. - **Life-Threatening Viral Infections:** The company is exploring the potential of the Hemopurifier for the treatment of life-threatening highly glycosylated viruses. - **Pre-Clinical Exploration:** The company is exploring additional clinical uses for the Hemopurifier, including the removal of extracellular vesicles and their microRNA cargo from acellular perfusates of discarded kidneys. **Future Outlook:** - The company plans to continue its clinical trials and explore additional indications for the Hemopurifier. - The company expects to incur losses for the foreseeable future and requires additional working capital to achieve its business objectives. **Risk Factors:** - **Financial Condition:** The company has incurred significant losses and expects to continue to incur losses for the foreseeable future. - **Regulatory Approval:** The company faces risks related to obtaining regulatory approval for its products. - **Market Position Changes:** The company faces competition from other medical device companies and may not be able to compete effectively. **Financial Condition:** - **Cash and Cash Equivalents:** As of March 31, 2025, the company had cash and cash equivalents of $5,501,261. - **Working Capital:** As of March 31, 2025, the company had working capital of $4,050,514. **Market Position Changes:** - The company is subject to intense competition, government regulation, and rapid technological change. - The company's operations are subject to significant risks and uncertainties, including financial, operational, technological, and regulatory risks. **Note:** The company's stock is listed on the Nasdaq Capital Market under the ticker symbol AEMD.